SCTC21C added to standard drugs for newly diagnosed multiple myeloma not suited for transplant
Tests adding SCTC21C to standard treatment in adults newly diagnosed with multiple myeloma.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 3
Where in China
- Beijing Chaoyang Hospital affiliated to Capital Medical UniversityBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sinocelltech Ltd.
- Trial code
- NCT07297329
- Record updated
- 29 January 2026
- Original description
The purpose of this study is to evaluate if the addition of SCTC21C to bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma not eligible for transplant will prolong progression-free survival (PFS) and/or improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.Read full original descriptionShow less
A Phase 3 Randomized, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
The purpose of this study is to evaluate if the addition of SCTC21C to bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma not eligible for transplant will prolong progression-free survival (PFS) and/or improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.
Inclusion: Newly diagnosed multiple myeloma (IMWG criteria) not eligible for transplant; Evidence of measurable disease; With adequate organ function and hematological parameters; Contraception，and during the study period and for 5 months after the last dose, all subjects must not donate reproductive cells.
Exclusion: Subjects who have undergone major surgery or experienced significant trauma within 4 weeks prior to the first use of the investigational drug, or who require elective surgery during the trial period; Received a live or attenuated vaccine within 30 days prior to the first dose; Female subjects who are currently breastfeeding; Other hematologic malignancies; Uncontrolled infection; Subjects with conditions that may affect safety or efficacy assessments include, but are not limited to, cardiovascular, respiratory, endocrine/metabolic, immune system, hepatic, gastrointestinal (such as gastrointestinal bleeding, perforation, ulcers, etc.), and malignant neoplasms, and are deemed clinically significant by the investigator; Subjects with mental disorders or poor compliance, or other circumstances deemed unsuitable for participation in this study by other investigators; Subjects with confirmed or suspected central nervous system infiltration or meningeal involvement.